We thank Xianglin Hu and colleagues for their interest and questions on the AcSé Pembrolizumab trial in chordoma,1 a rare sarcoma with no standard treatments in advanced phase.2–5
[Correspondence] Pembrolizumab monotherapy for advanced chordoma – Authors’ reply
For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –
LATEST
Sign up for our emails
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Newsletter
Privacy Policy